Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma
- 18 July 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 16 (9) , 3904-3915
Abstract
Melanocortin 1 receptor (MC1R) is under investigation as a target for drug delivery for metastatic melanoma therapy and imaging. The purpose of this study was to determine the potential of using BRAF inhibitors (BRAFi) and histone deacetylase inhibitors (HDACi) to enhance the delivery of MC1R-targeted radiolabeled peptide ([212Pb]DOTA-MC1L) by pharmacologically upregulating the MC1R expression in metastatic melanoma cells and tumors. MC1R expression was analyzed in de-identified melanoma biopsies by immunohistochemical staining. Upregulation of MC1R expression was determined in BRAFV600E cells (A2058) and BRAF wild-type melanoma cells (MEWO) by quantitative real-time polymerase chain reaction, flow cytometry, and receptor-ligand binding assays. The role of microphthalmia-associated transcription factor (MITF) in the upregulation of MC1R was also examined in A2058 and MEWO cells. The effectiveness of [212Pb]DOTA-MC1L α-particle radiotherapy in combination with BRAFi and/or HDACi was determined in athymic nu/nu mice bearing A2058 and MEWO human melanoma xenografts. High expression of MC1R was observed in situ in clinical melanoma biopsies. BRAFi and HDACi significantly increased the MC1R expression (up to 10-fold in mRNA and 4-fold in protein levels) via MITF-dependent pathways, and this increase led to enhanced ligand binding on the cell surface. Inhibition of MITF expression antagonized the upregulation of MC1R in both BRAFV600E and BRAFWT cells. Combining [212Pb]DOTA-MC1L with BRAFi and/or HDACi improved the tumor response by increasing the delivery of 212Pb α-particle emissions to melanoma tumors via augmented MC1R expression. These data suggest that FDA-approved HDACi and BRAFi could improve the effectiveness of MC1R-targeted therapies by enhancing drug delivery via upregulated MC1R.Keywords
Funding Information
- National Center for Research Resources (1-S10-RR0125036-01)
- U.S. Nuclear Regulatory Commission (NRC-HQ-84-14-FOA-0003)
- National Institutes of Health (1-S10-RR025439-01, 1P50CA174521-01A1, 1R43CA203430-01, K25CA172218-01A1)
This publication has 72 references indexed in Scilit:
- Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repairBritish Journal of Cancer, 2013
- Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistanceNature Communications, 2012
- Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment OptionsCancer Research, 2011
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT SignalingCancer Discovery, 2011
- Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model SystemsClinical Cancer Research, 2011
- Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic AcidClinical Cancer Research, 2008
- Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITFPLOS ONE, 2008
- Mitf regulation of Dia1 controls melanoma proliferation and invasivenessGenes & Development, 2006
- Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomasProceedings of the National Academy of Sciences, 2006